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Abstract: Despite being categorized as a procedure associated with a low risk of iatrogenic hemorrhage,
percutaneous pleural drainage in patients taking the ubiquitous antiplatelet agent clopidogrel is still
commonly perceived as a risky proposition. There is mounting evidence, however, in support of the safety
of percutaneous needle procedures in persons receiving this medication. Establishing that these pleural
interventions can be performed safely without clopidogrel interruption would be of great clinical significance,
especially in those taking it for recent cardiac stenting and therefore in danger of stent thrombosis should
antiplatelet therapy (APT) be withheld. The purpose of the present review is to summarize the available data
from published studies and series of thoracentesis and chest tube insertion in patients exposed to clopidogrel.
Also incorporated into this review are relevant investigations from the thoracic surgery and interventional
radiology experience, which contribute indirect evidence and help shape the context for interpreting the
safety data reported in the pleural literature. At the end, an attempt is made to synthesize the current
knowledge on this topic into conclusions for guiding practice.
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Introduction
The hesitation on the part of many in the interventional
pulmonology community to perform percutaneous pleural
drainage in patients receiving clopidogrel is an extrapolation
of traditional surgical concerns about operating on patients
in the setting of profound platelet inhibition. When it comes
to hemostasis, the surgeon’s situation is both comparatively
advantageous and disadvantageous. On the one hand,
surgery is a more radical intervention than a percutaneous
procedure with the possibility of major vascular injury.
On the other hand, the surgeon has better access to the
site of iatrogenic bleeding and has the technical ability to
achieve hemostasis by means of immediate operative repair.
Solving this problem by suspending clopidogrel therapy
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constitutes a potentially significant safety compromise,
especially in patients who have undergone recent coronary
stenting. Moreover, pleural drainage is often urgent
enough to preclude the possibility of delaying it until
the effect of clopidogrel dissipates. In the current era of
routine ultrasound (US) guidance and shift to smaller
tubes, the possibility that percutaneous pleural drainage
can be performed safely while continuing clopidogrel is
being raised increasingly in interventional pulmonology
circles (1). In this review, we familiarize the reader with
the pharmacology of clopidogrel, review the risks posed
by its periprocedural discontinuation, discuss potentially
applicable data from the thoracic surgery and interventional
radiology literature, and summarize the available studies of
percutaneous pleural drainage in those taking clopidogrel.
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Figure 1 Graphical representation of the mechanism of action of the clinically important thienopyridines, clopidogrel and prasugrel,
as well as of other antiplatelet agents. Of note, although it is also an antagonist of the P2Y12 receptor, ticagrelor does not belong to the
thienopyridine family. AA, arachidonic acid; COX-1, cyclooxygenase-1; CP450, cytochrome P450; P2Y12, purinergic receptor P2Y;
GPIIb/IIIa, glycoprotein IIb/IIIa; TXA2, thromboxane A2. Adapted from Kandan et al. (25) [© 2010 Radcliffe Cardiology. Figure
reproduced with permission].

Finally, we attempt to draw conclusions for clinical practice
based on the totality of current evidence.
Background of thienopyridines
Platelet plugs serve as the initial mechanism of hemostatic
repair of vascular endothelial injury and are eventually
reinforced by a fibrin mesh to form a mature clot. For
therapeutic inhibition of clotting, platelet receptors
regulating activation and aggregation, such as the
adenosine diphosphate (ADP) receptor P2Y12, have long
been attractive targets (2). The thienopyridines were the
first class of medications developed to antagonize the
ADP P2Y12 receptor. Members of this drug class, which
includes ticlopidine, clopidogrel, and prasugrel, exert
their antiplatelet effect by irreversibly blocking the P2Y12
receptor from interacting with its ligand ADP (3). This
interrupts the cascade of platelet activation and aggregation
that ultimately leads to clot formation (3-6). The inhibitory
effect of these medications lasts for the lifetime of the
platelet (7).
All thienopyridines are oral prodrugs that require
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conversion to active metabolites (3,8). Ticlopidine and
clopidogrel require two conversion steps to generate their
active metabolites, which results in a delayed onset of
action (9,10). Once cumulative dosing reaches a therapeutic
level, however, recovery of platelet function after drug
withdrawal occurs slowly (3,11). Prasugrel has a more rapid
onset of action and requires only one step to generate
its active metabolites (3). The clinical use of the firstgeneration agent ticlopidine has been limited by bone
marrow toxicity (12). Third-generation prasugrel has the
most potent inhibitory effect, but this advantage is offset by
its tendency to increase bleeding events (13-15). As a result,
clopidogrel—the second-generation thienopyridine—
remains the most widely used option in this drug class. It
suffers from great variability of the antiplatelet response
due in part to different rates of absorption and to
polymorphisms of the regulatory gene CYP2C19 involved
in the generation of its active metabolites (3,13,16).
Clopidogrel has a half-life of approximately 8 hours with
platelet inhibition starting at 48 hours with daily oral dosing
of 50–100mg. Steady state levels are reached after 4–7 days,
and the antiplatelet effect lingers for 7–10 days (17,18).
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Despite these shortcomings, clopidogrel is well-established
therapy for patients with cerebrovascular disease, peripheral
vascular disease, acute coronary syndromes, and for those
undergoing percutaneous coronary intervention (PCI),
particularly with stent placement (14,19-24). Figure 1
graphically illustrates the mechanism of action of the
thienopyridines as well as other commonly used antiplatelet
agents.
Cardiac risks of clopidogrel discontinuation
Patients with recently placed coronary stents on APT that
includes clopidogrel pose a clinical dilemma if non-cardiac
surgery is required. On one side are fears about increased
bleeding risk and failure of intraoperative hemostasis. On
the other is this population’s predisposition to adverse
perioperative cardiac events if APT is discontinued
prematurely (26,27). In patients with coronary stents,
premature discontinuation of clopidogrel is associated with
an increased risk for thrombosis (13,28,29), myocardial
infarction (30), and an increase in overall mortality
(29,31,32). This is particularly true for those receiving
drug-eluting stents (DES) because several studies have
reported a 29% or greater increase in the risk of coronary
thrombosis if clopidogrel is withdrawn prematurely
(17,29,33). In a prospective multi-center, observational
cohort of 1,134 patients with coronary stents, the strongest
independent risk factor for stent thrombosis within
30 days of PCI was the absence of clopidogrel therapy.
There was also a strong association with stent thrombosis
if clopidogrel was discontinued between 30 days and
6 months, and even beyond 6 months of the index PCI (34).
A systematic review and meta-analysis found that after the
recommended minimum 12-month period of dual APT for
DES, there is still an increased risk for death and coronary
events associated with stopping these medications (35). Data
suggest that the most significant independent risk factor
for perioperative coronary stent thrombosis and myocardial
infarction is the discontinuation of oral APT for more than
5 days prior to non-cardiac surgery (13,36,37).
Thoracic surgery and clopidogrel
Historically, thoracic surgeons have been reluctant to
operate in the chest of patients obligated to take clopidogrel
for recent cardiac stenting. This poses a problem when the
surgery is urgent, such as in the case of empyema, and even
when it is time-sensitive, such as resection of lung cancer.
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Cerfolio et al. were the first to publish their experience of
performing thoracic surgery without interruption of APT,
which could have been clopidogrel alone or clopidogrel
plus aspirin (17). None of the 27 patients whom they took
to the operating room (OR) on APT for primary surgery
required blood transfusions or re-operation for bleeding.
However, both patients taking aspirin and clopidogrel who
were undergoing repeat thoracic surgery required a return
to the OR for bleeding. Additionally, the patients receiving
APT at the time of surgery had a significantly greater chest
tube output during the first 2 post-operative days. Of note,
this series did not include any operations in the pleural
space. Ceppa et al. subsequently analyzed 54 patients who
underwent mostly thoracoscopic lung cancer resection
during treatment with clopidogrel and compared them to
108 historical, propensity score matched controls not treated
with clopidogrel perioperatively (38). Only one patient,
from the control group, required reoperation for bleeding.
There was no difference between the groups in the need
for blood transfusion or prolonged chest tube drainage.
Yu et al. reported a series of 58 patients who underwent
lung resectional surgery on APT; half were taking
clopidogrel (n=18) or clopidogrel plus aspirin (n=11) (39).
Three patients experienced post-operative bleeding, all were
recipients of dual therapy, but none required re-operation.
Four of the 11 dual therapy patients received blood
transfusions postoperatively, and all four had extensive
pleural adhesions encountered at surgery. The dual therapy
patients had significantly greater chest tube output than
those receiving other forms of APT. Within the limitations
of available data, initial resectional thoracic surgery on APT
appears to be safe, with the caveat that operations on dual
therapy that require extensive lysis of pleural adhesions
may be associated with bleeding complications. However,
there is no existing evidence on the safety of primary
pleural surgery in patients receiving clopidogrel alone or in
combination.
Interventional radiology procedures and
clopidogrel
There are limited data on the safety of percutaneous
procedures performed under radiological guidance in
persons taking clopidogrel. While recommendations from
the OR may be extrapolated to image-guided percutaneous
procedures, the inability of the interventionalist to directly
visualize and promptly control bleeding presents a unique
risk (40). In 2012, the Society of Interventional Radiology
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(SIR) published consensus guidelines for periprocedural
antiplatelet management according to the bleeding risk
of each percutaneous image-guided intervention. All
recommendations were based on the assumption of an
elective interventional procedure and of a single hemostatic
defect (41).
Procedures labeled as category 1 are considered to have
a low-risk of bleeding, which would be easily detected
and managed. These include drainage catheter exchange,
thoracentesis, paracentesis, superficial abscess drainage,
joint aspiration and injection, and superficial aspiration or
biopsy. The recommendation is to withhold clopidogrel
for 0–5 days prior to such interventions and to continue
aspirin therapy. Category 2 procedures are associated with
a moderate risk of bleeding, and the recommendation is
to continue aspirin and hold clopidogrel for 5 days. This
category includes biopsies of the chest wall and lung as well
as intra-abdominal and retroperitoneal abscess drainage or
biopsy. Category 3 procedures, such as renal biopsy, pose
the highest risk of bleeding, which would be difficult to
identify and control. Both aspirin and clopidogrel should be
held for 5 days prior to these procedures according to the
SIR guidelines.
In the years since the SIR guidelines were issued, only
two studies directly addressing APT management for
percutaneous interventions by interventional radiologists
have been published. One large retrospective study of
image-guided percutaneous deep core needle biopsies
found the overall incidence of major bleeding events to
be low (0.5%) (42). In the subset of 246 patients who
were taking clopidogrel in proximity to the procedure,
there was only one major bleeding event (0.41%), which
occurred in a patient within 7 days of clopidogrel ingestion.
Limitations of this study include inconsistent data about
the timing of last clopidogrel exposure and about aspirin
co-administration. More informative is a recent study by
Pieper et al. of 63 patients who had undergone various
image-guided core needle biopsies. All subjects took
clopidogrel within 5 days of the procedure with a mean
abstinence time of 2.9 days prior to needle insertion. Twelve
procedures were performed within 24 hours of clopidogrel
ingestion. There were 48 patients (76%) who also took
aspirin within 5 days of the procedure (43). There was only
one significant iatrogenic bleeding event (1/63; 1.6%),
which occurred after laceration of an intercostal artery
during CT-guided pulmonary nodule biopsy.
Aggregating the encouraging, albeit limited, safety
data on performing category 2 and 3 percutaneous needle
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procedures and even certain types of thoracic surgery
in patients receiving clopidogrel, one might reasonably
conclude that category 1 procedures, such as thoracentesis,
should fare as well as, if not better than, these higher risk
interventions. However, there is a paucity of direct evidence
confirming the safety of clopidogrel use in category
1 percutaneous needle procedures. Fortunately, whatever
data do exist come predominantly from studies of
thoracentesis and chest tube insertion.
Percutaneous pleural procedures and
clopidogrel
As mentioned, thoracentesis is categorized as a low-risk
procedure for bleeding according to expert opinion and
guidelines (40,44). The bleeding concern relates primarily
to iatrogenic hemothorax from injury of the intercostal
artery, and less so bleeding from damage to a viscus, such
as might occur if the spleen is inadvertently punctured. US
guidance improves procedural accuracy in thoracentesis,
so sub-diaphragmatic entry should be less of a concern
in the US era (45). The ability of color Doppler US to
identify intercostal vessels when selecting the safest site for
thoracentesis has been demonstrated, but this step has not
been universally adopted in clinical practice (46). When
performed by experienced operators with standard US
guidance, the overall hemothorax rate is exceedingly low.
In their published experience with over 9,300 thoracentesis
procedures, Ault et al. recorded only 5 hemothoraces, a
rate of 0.05% (47). When large data sets from the Mayo
Clinic were retrospectively analyzed, there were no
hemothoraces even in patients who underwent thoracentesis
with abnormal coagulation parameters, which casts doubt
on the need for routine laboratory studies prior to this
procedure (48,49). Likewise, no hemothoraces occurred
in 60 patients with thrombocytopenia (<50 K/µL) or
coagulopathy [international normalized ratio (INR) >1.5]
subjected to thoracentesis as part of a prospective
observational cohort at Yale-New Haven Hospital (50).
A separate body of literature exists on the safety
of performing pleural drainage in patients receiving
clopidogrel. For study purposes, thoracentesis and smallbore (i.e., ≤14 French) chest tube placement are considered
to be analogous. This is a reasonable assumption because
small-bore chest tubes placed using the Seldinger
technique have a comparably favorable safety profile to
that of thoracentesis (51,52). In fact, in some institutions,
therapeutic thoracentesis may consist of the temporary
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Table 1 Summary of five available studies reporting bleeding rates associated with pleural drainage on clopidogrel
Authors

Study type

Procedure(s)

Number of
procedures

Percentage of patients with Major bleeding
concurrent aspirin use
events

Chest
Thoracentesis
tubes

Dammert et al.,
2013 (54)

Retrospective

Chest tubea

43a

91%

None

43

0

Abouzgheib
et al., 2012 (53)

Retrospective

Chest tubeb

24b

72%

None

24

0

Mahmood
et al., 2014 (55)

Prospective

Chest tube and
thoracentesis

25c

88%

1/25; 4%d

8

17

Zalt et al.,
2012 (36)

Prospective

Thoracentesis

45e

Not reported

None

0

45

Puchalski et al.,
2013 (50)

Prospective

Thoracentesis

18f

Not reported

None

0

18

–

–

155

–

1

75

80

Total
Major bleeding

–

–

a

–

–

1/155; 0.6%

0

1/80; 1.25%

b

, 43 procedures in 30 patients: 8 Fr =11, 14 Fr =27, 16 Fr =5; , 24 procedures in 18 patients: 8 Fr =9, 10 Fr =1, 12 Fr =3, 14 Fr =1, 16 Fr
=10; c, 25 procedures in 25 patients: 17 thoracenteses and 8 chest tubes (all 14 Fr); d, 1 patient with hemothorax after thoracentesis while
on clopidogrel and aspirin; e, 45 procedures in 30 patients; f, 18 procedures in 18 patients.

insertion of a very small (e.g., eight French) pigtail catheter
into the pleural space, in which case the two procedures
are essentially indistinguishable. There are some practical
differences, however, between the two procedures in the
event of a hemothorax caused by the procedure itself. One
is that an iatrogenic hemothorax should be apparent more
quickly when the drainage catheter is left in place based on
the appearance of the output. Another is that the placement
of a drain is in itself the first step in the management of
an iatrogenic hemothorax until it is determined whether a
hemostatic intervention is required.
The retrospective data on pleural drainage and
clopidogrel encompass a total of 54 patients across two
studies who underwent 67 US-guided small-bore chest
tube insertions (53,54). No life-threatening bleeding
was reported in any of these procedures. In the earliest
prospective study, Zalt et al. performed 45 US-guided
thoracentesis procedures in 30 patients on clopidogrel,
and in their sample there was 1 instance of a superficial
hematoma at the puncture site that did not lead to a
significant drop in hemoglobin (36). Mahmood et al.
prospectively enrolled 25 consecutive subjects who
underwent thoracentesis or small-bore chest tube placement
while taking clopidogrel and compared this group to
50 contemporaneous patients who likewise underwent
pleural drainage but without clopidogrel (55). There
was one hemothorax during the study, which occurred
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in the clopidogrel cohort, as indicated by a 1.6 gm/dL
decrease in hemoglobin post-procedure in conjunction
with increased pleural effusion on chest X-ray. The
hemothorax was managed successfully with small-bore chest
tube placement. Puchalski et al. conducted a prospective
study of 312 thoracentesis patients, 130 of whom had an
increased bleeding risk as defined by the investigators (50).
Eighteen of the 130 patients (14%) assigned to the increased
risk group were being actively treated with clopidogrel;
8 of these 18 also had other predispositions to bleeding.
No hemothoraces occurred in the entire study, and the
change in hematocrit post procedure was not significantly
different between those with and without a bleeding risk.
Taken together, these small studies report one instance of
hemothorax in a sample of 155 pleural procedures. This
translates to a bleeding rate of 0.6%, which is still higher
than that in the study by Ault et al. quoted above in a general
population undergoing thoracentesis but is comparable to,
for example, conventional transbronchial biopsy in persons
not taking antiplatelet agents and is certainly lower than
that reported for bronchoscopic cryobiopsy (56,57). Table 1
summarizes and aggregates the bleeding rates reported by
the aforementioned studies.
Conclusions
At the present time, only observational data are available to
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guide conclusions about the safety of percutaneous pleural
drainage in patients taking clopidogrel. In aggregate, the
evidence allows one to conclude that urgent percutaneous
pleural drainage using current techniques can be performed
with an acceptable safety profile in patients treated with
clopidogrel. Of course, if deemed feasible, a lower bleeding
risk would be achieved if the drainage were delayed for at
least 5 days while the clopidogrel is withheld. Concordant
results of larger, collaborative, ideally prospective
randomized studies, or at least big registry data, are needed
to strengthen the level of confidence in such an approach to
this challenging clinical scenario.
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